SLC1A5 and melanoma: In contrast, in melanoma patients from the Nathanson_2017 cohort, it was observed that patients with low expression of SLC1A5 who received ai_CTLA-4 treatment had a worse prognosis (Supplementary Figures 2D and 3D).